PL3336192T3 - Wektor transkrypcyjny rna i jego zastosowanie - Google Patents

Wektor transkrypcyjny rna i jego zastosowanie

Info

Publication number
PL3336192T3
PL3336192T3 PL18153133T PL18153133T PL3336192T3 PL 3336192 T3 PL3336192 T3 PL 3336192T3 PL 18153133 T PL18153133 T PL 18153133T PL 18153133 T PL18153133 T PL 18153133T PL 3336192 T3 PL3336192 T3 PL 3336192T3
Authority
PL
Poland
Prior art keywords
rna transcription
transcription vector
vector
rna
transcription
Prior art date
Application number
PL18153133T
Other languages
English (en)
Inventor
Carlo Heirman
Kristiaan Thielemans
Original Assignee
Vrije Universiteit Brussel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vrije Universiteit Brussel filed Critical Vrije Universiteit Brussel
Publication of PL3336192T3 publication Critical patent/PL3336192T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/50Methods for regulating/modulating their activity
    • C12N2320/52Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/10Vectors comprising a non-peptidic targeting moiety
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/50Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/10Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
PL18153133T 2013-11-12 2014-11-12 Wektor transkrypcyjny rna i jego zastosowanie PL3336192T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13192555 2013-11-12
EP14799996.5A EP3068888B1 (en) 2013-11-12 2014-11-12 Rna transcription vector and uses thereof
PCT/EP2014/074349 WO2015071295A1 (en) 2013-11-12 2014-11-12 Rna transcription vector and uses thereof
EP18153133.6A EP3336192B1 (en) 2013-11-12 2014-11-12 Rna transcription vector and uses thereof

Publications (1)

Publication Number Publication Date
PL3336192T3 true PL3336192T3 (pl) 2022-04-04

Family

ID=49578161

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18153133T PL3336192T3 (pl) 2013-11-12 2014-11-12 Wektor transkrypcyjny rna i jego zastosowanie
PL14799996T PL3068888T3 (pl) 2013-11-12 2014-11-12 Wektor transkrypcyjny rna oraz jego zastosowania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14799996T PL3068888T3 (pl) 2013-11-12 2014-11-12 Wektor transkrypcyjny rna oraz jego zastosowania

Country Status (20)

Country Link
US (3) US10159755B2 (pl)
EP (2) EP3068888B1 (pl)
JP (2) JP6530393B2 (pl)
KR (2) KR102396589B1 (pl)
CN (2) CN111621524A (pl)
AU (1) AU2014350222B2 (pl)
CA (2) CA3191243A1 (pl)
DK (2) DK3336192T3 (pl)
EA (1) EA035313B1 (pl)
ES (2) ES2666380T3 (pl)
HK (1) HK1226097A1 (pl)
HU (2) HUE058792T2 (pl)
IL (1) IL245596B (pl)
MX (1) MX2016006134A (pl)
NO (1) NO3068888T3 (pl)
NZ (1) NZ720885A (pl)
PL (2) PL3336192T3 (pl)
PT (2) PT3336192T (pl)
SG (1) SG11201603482RA (pl)
WO (1) WO2015071295A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
EP3334828B1 (en) * 2015-08-10 2020-10-28 CureVac Real Estate GmbH Method of increasing the replication of a circular dna molecule
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
KR20190127655A (ko) 2016-10-19 2019-11-13 프로디자인 소닉스, 인크. 음향학에 의한 친화성 세포 추출
KR102439221B1 (ko) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
WO2020141212A1 (en) 2019-01-04 2020-07-09 Etherna Immunotherapies Nv Mrna vaccine
KR20220007850A (ko) 2019-03-13 2022-01-19 이더알엔에이 이뮤노테라피스 엔브이 Mrna 백신
WO2020216911A1 (en) 2019-04-26 2020-10-29 Etherna Immunotherapies Nv Mrna formulation
BR112021025170A2 (pt) 2019-06-27 2022-01-25 Etherna Immunotherapies Nv Terapia de combinação
AU2021211894A1 (en) 2020-01-21 2022-09-01 Etherna Immunotherapies Nv Lipid nanoparticles
CN115443148B (zh) 2020-02-14 2024-08-06 伊泽阿恩埃免疫疗法股份有限公司 鼻内mRNA疫苗
EP4164596A1 (en) 2020-06-11 2023-04-19 eTheRNA Immunotherapies NV Lipid nanoparticles
CN118556131A (zh) * 2022-01-27 2024-08-27 爱思开生物科技有限公司 用于蛋白质表达的mRNA及其模板
KR102669481B1 (ko) 2022-03-15 2024-05-28 주식회사 협일공조 필터교체가 용이한 디퓨저
KR102624969B1 (ko) * 2023-04-03 2024-01-16 한국과학기술원 mRNA 번역 증가를 유도하는 mRNA 3'UTR 서열

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
US5861240A (en) * 1996-02-28 1999-01-19 The Regents Of The University Of California Isolated human herpesvirus type 8 sequences and uses thereof
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
AU3117101A (en) * 2000-01-28 2001-08-07 Scripps Research Inst Synthetic internal ribosome entry sites and methods of identifying same
US7468275B2 (en) * 2000-01-28 2008-12-23 The Scripps Research Institute Synthetic internal ribosome entry sites and methods of identifying same
US7608699B2 (en) * 2003-12-29 2009-10-27 Rockefeller University Synthetic nuclear localization signal derived from lentiviral integrase and methods of use thereof
US8394777B2 (en) * 2004-06-04 2013-03-12 Centre National De La Recherche Scientifique Treating immunodeficiencies by intrathymic injection of nucleotide sequences
JP4964493B2 (ja) * 2006-04-28 2012-06-27 株式会社カネカ 内部リボソーム結合部位を利用した遺伝子組換え全抗体の効率的生産法
PL2201100T3 (pl) * 2007-09-14 2016-10-31 Wzmacnianie zdolności ludzkich komórek prezentujących antygen do stymulacji komórek T i ich zastosowanie w szczepieniu
EP2610341B1 (en) * 2007-12-11 2014-09-17 The Scripps Research Institute Compositions and methods related to mRNA translational enhancer elements
BRPI0907501B1 (pt) * 2008-02-01 2021-02-23 Ceres, Inc construto de vetor, método para dirigir a transcrição, método de expressão de uma região de codificação exógena, método de alteração da expressão de um gene e método de produção de uma planta transgênica

Also Published As

Publication number Publication date
NZ720885A (en) 2022-02-25
US20210060182A1 (en) 2021-03-04
US20160279266A1 (en) 2016-09-29
SG11201603482RA (en) 2016-05-30
KR20210076181A (ko) 2021-06-23
US10864284B2 (en) 2020-12-15
EP3068888A1 (en) 2016-09-21
PT3336192T (pt) 2022-03-10
ES2908268T3 (es) 2022-04-28
JP6900054B2 (ja) 2021-07-07
PT3068888T (pt) 2018-04-24
NO3068888T3 (pl) 2018-06-30
CN111621524A (zh) 2020-09-04
EA035313B1 (ru) 2020-05-27
CA2929203A1 (en) 2015-05-21
KR20160090317A (ko) 2016-07-29
MX2016006134A (es) 2017-01-20
ES2666380T3 (es) 2018-05-04
US10159755B2 (en) 2018-12-25
IL245596A0 (en) 2016-06-30
HK1226097A1 (zh) 2017-09-22
CA3191243A1 (en) 2015-05-21
CN105849269A (zh) 2016-08-10
CN105849269B (zh) 2020-07-17
CA2929203C (en) 2023-04-18
AU2014350222A1 (en) 2016-06-23
KR102396589B1 (ko) 2022-05-10
JP2016537978A (ja) 2016-12-08
EP3336192A1 (en) 2018-06-20
PL3068888T3 (pl) 2018-07-31
JP2019146589A (ja) 2019-09-05
EP3336192B1 (en) 2021-12-08
EA201690965A1 (ru) 2016-09-30
IL245596B (en) 2019-10-31
EP3068888B1 (en) 2018-01-31
BR112016010595A2 (pt) 2017-12-05
US20180353625A1 (en) 2018-12-13
KR102267412B1 (ko) 2021-06-21
WO2015071295A1 (en) 2015-05-21
AU2014350222B2 (en) 2020-02-27
DK3336192T3 (da) 2022-03-14
HUE058792T2 (hu) 2022-09-28
JP6530393B2 (ja) 2019-06-12
DK3068888T3 (en) 2018-05-07
HUE038831T2 (hu) 2018-11-28

Similar Documents

Publication Publication Date Title
HK1226097A1 (zh) Rna轉錄載體及其用途
IL269461B (en) Cytidine-5-carboxamide modified nucleotide preparations and related methods
ZA201602510B (en) Strigolactone formulations and uses thereof
EP2972349A4 (en) POLYMER POINT COMPOSITIONS AND CORRESPONDING METHODS
IL245839A0 (en) Inhibitors of rna polymerase i and use of preparations containing them for treatment
EP2988742A4 (en) THIAZOLES AND USES THEREOF
EP2918681A4 (en) FERTILITY GENE AND USES THEREOF
EP3048538A4 (en) Vector operation core and vector processor
IL240248A0 (en) Met-binding substances and their uses
PL2964767T3 (pl) Geny kodujące toksyny i sposoby ich zastosowania
AP2016009207A0 (en) Genetic markers and uses therefor
HK1231503A1 (zh) 基因突變體及其應用
SG11201600235TA (en) Castings and manufacture methods
GB201309178D0 (en) Enzyme and uses thereof
GB201320992D0 (en) Complex and uses thereof
EP2970895A4 (en) PODOCYTIC CULTURES AND USES THEREOF
ZA201601880B (en) Hetero-transglycosylase and uses thereof
WO2014202624A9 (en) Rasamsonia gene and use thereof
GB201305297D0 (en) Novel agents and uses thereof
GB201304585D0 (en) Methods and product
GB201301393D0 (en) Kiddibidet and pottibidet
GB201318949D0 (en) Genes
GB201304166D0 (en) CelebQuiff and Instant Quiff
GB201309328D0 (en) Product and use thereof
GB201306435D0 (en) Vector